Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation (MANTRA-PAF)
Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Paroxysmal atrial fibrillation, Heart arrhythmia, Ablation, Drug treatment
Eligibility Criteria
Inclusion Criteria: Patients ≤ 70 years of age Paroxysmal atrial fibrillation patients who are considered as being candidates for antiarrhythmic drug therapy initiation Patients who have had at least two episodes of symptomatic paroxysmal atrial fibrillation in the foregoing 6 months can be included. The atrial fibrillation episodes may be persistent (need DC- or AAD-conversion) with a duration of less than 7 days. Exclusion Criteria: Previous or ongoing chronic treatment with class IC or class III antiarrhythmic drugs Intolerance/contraindication to class IC and class III antiarrhythmic drugs (i.e. intolerance/contraindication to only one of the two groups is not excluding the patient) Previous atrial fibrillation ablation Severely increased left atrial size Left ventricular ejection fraction below 0.40 (during sinus rhythm or atrial fibrillation with RR-intervals above 600 ms) or "eye-balled" reduction of systolic function to less than "moderately decreased". Contraindication to anticoagulation treatment with vitamin K antagonists Expected surgery for structural heart disease within the follow-up period Significant mitral valve disease New York Heart Association (NYHA) III-IV Planned pregnancy within the follow-up period Secondary atrial fibrillation (e.g. post-surgery, infections, hyperthyroidism) Age < 18 years Patient does not want to participate.
Sites / Locations
- Department of Cardiology
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1
2
Antiarrythmic drug treatment